T-Lymphoblastic Lymphoma

  • Soumya Pandey
  • Terry HarvilleEmail author


  • The highest-resolution HLA typing is thought to provide the best opportunity for matching a patient with a donor in order to reduce the risks for graft-versus host disease (GVHD) and graft rejection

  • Linkage disequilibrium is an important concept regarding HLA type associations, and can be used to help surmise which HLA alleles may be present, while actual typing is typically necessary for confirmation of the results

  • The use of “Common and Well-Documented” alleles is also helpful in determination of the present HLA types

  • Currently, the NMDP does not consider matching for HLA-DRB3, -DRB4, -DRB5, or -DQ to be relevant for hematopoietic cell transplantation (HCT). However, in clinical practice, many transplanters prefer donors matched for these alleles as well

  • HLA-DPB1 is now recognized to be relevant for HCT

  • Matching can occur at two levels; first, the two-field nomenclature match and second, the examination of T cell epitope (TCE) groups for permissive versus non-permissive mismatching of HLA-DPB1

  • Long-term outcomes are similar to those with the HLA-DPB1 two-field nomenclature match and HLA-DPB1 TCE permissive mismatches

  • Cytomegalovirus status match of the patient and donor is a critical factor for successful HCT outcomes

  • The NMDP website provides invaluable information regarding HLA typing and HCT outcomes


Graft-versus host disease (GvHD) NMDP Cytomegalovirus HLA-DPB1 


  1. 1.
    Rimsza L, Pittaluga S, Dirnhofer S, Copie-Bergman C, de Leval L, Facchetti F, Pileri S, Rosenwald A, Wotherspoon A, Fend F. The clinicopathologic spectrum of mature aggressive B cell lymphomas. Virchows Archiv. 2017;471(4):453–66.CrossRefGoogle Scholar
  2. 2.
    Spellman S, Setterholm M, Maiers M, Noreen H, Oudshoorn M, Fernandez-Vina M, Petersdorf E, Bray R, Hartzman RJ, Ng J, Hurley CK. Advances in the selection of HLA-compatible donors: refinements in HLA typing and matching over the first 20 years of the National Marrow Donor Program Registry. Biol Blood Marrow Transpl. 2008;14(9 Suppl):37–44.CrossRefGoogle Scholar
  3. 3.
    Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringden O, Rozman C, Speck B, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75(3):555–62.CrossRefGoogle Scholar
  4. 4.
    Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, van Rhee F, Mittermueller J, de Witte T, Holler E, Ansari H. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86(5):2041–50.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of Pathology and Laboratory ServicesUniversity of Arkansas for Medical SciencesLittle RockUSA
  2. 2.Departments of Pediatrics and Internal MedicineUniversity of Arkansas for Medical SciencesLittle RockUSA

Personalised recommendations